Fuller & Thaler Asset Management Inc. Has $287.79 Million Holdings in Exelixis, Inc. $EXEL

Key Points

• Fuller & Thaler Asset Management has increased its stake in Exelixis by 2.2%, making the stock its 9th largest position with approximately 7.8 million shares valued at around $287.8 million.
• Exelixis's recent earnings report showed an EPS of $0.75 which exceeds estimates, but revenue fell by 10.8% year-over-year to $568.26 million.
• Exelixis has received mixed ratings from analysts, with a consensus of 14 buy ratings and a target price of $44.06, while some analysts downgraded the stock to a "buy" rating.

Fuller & Thaler Asset Management Inc. boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 2.2% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 7,795,074 shares of the biotechnology company's stock after purchasing an additional 164,134 shares during the period. Exelixis comprises 1.1% of Fuller & Thaler Asset Management Inc.'s holdings, making the stock its 9th largest position. Fuller & Thaler Asset Management Inc. owned approximately 2.83% of Exelixis worth $287,794,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Coppell Advisory Solutions LLC bought a new position in shares of Exelixis in the 4th quarter valued at about $25,000. Hemington Wealth Management lifted its position in Exelixis by 211.3% during the first quarter. Hemington Wealth Management now owns 769 shares of the biotechnology company's stock worth $28,000 after acquiring an additional 522 shares during the last quarter. Colonial Trust Co SC lifted its position in Exelixis by 616.9% during the fourth quarter. Colonial Trust Co SC now owns 889 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 765 shares during the last quarter. Bartlett & CO. Wealth Management LLC acquired a new stake in Exelixis during the first quarter worth approximately $37,000. Finally, Costello Asset Management INC bought a new position in shares of Exelixis during the first quarter worth approximately $39,000. Institutional investors own 85.27% of the company's stock.

Insider Buying and Selling at Exelixis

In other Exelixis news, Director Jack L. Wyszomierski sold 7,535 shares of Exelixis stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $43.09, for a total value of $324,683.15. Following the completion of the sale, the director directly owned 358,882 shares of the company's stock, valued at approximately $15,464,225.38. The trade was a 2.06% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Sue Gail Eckhardt sold 18,838 shares of the business's stock in a transaction dated Monday, June 2nd. The stock was sold at an average price of $42.74, for a total transaction of $805,136.12. Following the sale, the director directly owned 21,380 shares of the company's stock, valued at approximately $913,781.20. The trade was a 46.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. 2.82% of the stock is owned by insiders.

Exelixis Stock Performance

Shares of NASDAQ:EXEL traded down $0.08 during mid-day trading on Friday, reaching $38.63. 1,509,748 shares of the company's stock were exchanged, compared to its average volume of 3,044,251. The firm has a market capitalization of $10.40 billion, a price-to-earnings ratio of 18.57, a PEG ratio of 0.78 and a beta of 0.29. The business's fifty day moving average price is $41.62 and its 200-day moving average price is $39.25. Exelixis, Inc. has a twelve month low of $25.12 and a twelve month high of $49.62.

Exelixis (NASDAQ:EXEL - Get Free Report) last issued its quarterly earnings results on Monday, July 28th. The biotechnology company reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.63 by $0.12. The company had revenue of $568.26 million for the quarter, compared to analyst estimates of $574.36 million. Exelixis had a net margin of 27.01% and a return on equity of 27.47%. Exelixis's revenue was down 10.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.84 earnings per share. Exelixis has set its FY 2025 guidance at EPS. Analysts predict that Exelixis, Inc. will post 2.04 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on EXEL. Morgan Stanley decreased their price objective on shares of Exelixis from $48.00 to $46.00 and set an "overweight" rating on the stock in a research note on Tuesday, July 29th. William Blair reissued an "outperform" rating on shares of Exelixis in a research note on Tuesday, July 29th. HC Wainwright decreased their price objective on shares of Exelixis from $53.00 to $46.00 and set a "buy" rating on the stock in a research note on Tuesday, August 12th. Royal Bank Of Canada decreased their price objective on shares of Exelixis from $50.00 to $45.00 and set a "sector perform" rating on the stock in a research note on Tuesday, July 29th. Finally, Citigroup lifted their price objective on shares of Exelixis from $45.00 to $56.00 and gave the company a "buy" rating in a research note on Thursday, May 15th. Thirteen equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Exelixis presently has a consensus rating of "Moderate Buy" and a consensus price target of $44.06.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.